March 11, 2021 -- Real-world evidence released by the Israel Ministry of Health demonstrates dramatically lower incidence rates of COVID-19 disease in individuals fully vaccinated with the Pfizer-BioNTech COVID-19 vaccine.
The data confirm that the vaccine is effective in preventing symptomatic SARS-CoV-2 infection, COVID-19 cases, hospitalizations, severe and critical hospitalizations, and deaths. The data show that two weeks after the second vaccine dose, the vaccine effectiveness was at least 97% in preventing symptomatic disease, severe/critical disease, and death. The analysis found that the vaccine was 94% effective against asymptomatic SARS-CoV-2 infections.
The data were derived from de-identified aggregate Israel Ministry of Health surveillance data collected between January 17 and March 6, 2021, a time when the B.1.1.7 variant was the predominant strain in the country.
Following the authorization for emergency use of the Pfizer-BioNTech COVID-19 vaccine in Israel on December 6, 2020, the Israel Ministry of Health launched a national vaccination program targeting individuals age 16 years or older -- a total of 6.4 million people, representing 71% of the population. Israel regularly collects comprehensive, real-time data on SARS-CoV-2 testing, COVID-19 cases, including date of symptom onset, and vaccination history, through a nationally notifiable disease registry and the national medical record database.
In January, Pfizer and the Israel Ministry of Health entered into a collaboration agreement to monitor the real-world effect of the COVID-19 vaccine. The organizations plan to submit the data to a peer-reviewed journal.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
